Boston, MA: The Future of AI in Biotechnology

Artificial Intelligence (AI) and Machine Learning (ML) have woven their way into the vernacular of the biotechnology and healthcare industries. With access to big data and high capacity computing becoming more available, what are the impacts of these technologies to strategy, outcomes, and innovation in the biotech industry.


Cherié Butts Cherié Butts (Arts & Sciences '92), is Medical Director and Head of Human Biology Research – Digital & Quantitative Medicine at Biogen (Cambridge, MA). She obtained undergraduate and graduate degrees from The Johns Hopkins University. Her pre-doctoral studies at the University of Texas MD Anderson Cancer Center characterized anti-tumor immune responses in ovarian cancer patients and postdoctoral studies at the National Institutes of Health examined neuroendocrine regulation of innate immunity. She continued this work at the US Food & Drug Administration, taking on additional responsibilities of evaluating drug and biologics applications. At Biogen, she held various roles while continuing to conduct research. She delved into program and portfolio management – helping scientists and clinicians understand how potential new drugs address a specific unmet medical need for patients. She served on the Portfolio Transformation team, leading the probability of success theme and team learning & health initiative. Most recently, she was responsible for clinical trials in multiple sclerosis before moving into her current role that focuses on use of technologies as a mechanism for reducing clinical trial burden and ensuring trials better represent those afflicted with disease.

Dr. Butts is passionate about ensuring individuals from all backgrounds contribute to biomedical research. She works with scientific professional societies and related organizations to help scientists and clinicians learn about roles in government and industry – at and away from the bench or clinic. She currently serves on the Leadership Board and Research Affairs Oversight Committee of Beth Israel Deaconess Medical Center; Board of Directors of Keystone Symposia; Board of Trustees at Salem State University; Council of the Society of Leukocyte Biology; Endocrine Society Nominating Committee (chair); Massachusetts Economic Development Planning Council; and is Adjunct Professor at University of Maryland.


Ryan Bloom Dr. Ryan Bloom (Engineering '09), Associate Director, Corporate Development is an experienced Corporate Development professional with deep scientific expertise and diverse business experience covering search/evaluation, transactions, new product planning, alliance management, corporate strategy/finance, program and portfolio planning. Demonstrated ability to identify and evaluate business development opportunities and execute transactions. Expert knowledge of cell and gene therapy, immuno- oncology across diverse modalities. Strong business acumen with analytical and problem-solving skills to innovate across multiple disciplines.





Alex Harding Alex Harding, MD (SOM '15) is a senior associate and focuses on building companies to create life-changing therapies for patients. He is also a practicing physician who sees patients at Massachusetts General Hospital. His patients are the motivation for his work at Atlas.

At Atlas, Alex was on the founding team and now observes on the board of Triplet Therapeutics and several early stage companies. He also observes on the board of HotSpot Therapeutics and the Science & Technology committee of Synlogic. He observed on the board of Rodin Therapeutics before it was acquired.

Prior to joining Atlas in 2018, Alex completed his residency in internal medicine at Massachusetts General Hospital. He received an MD from Johns Hopkins School of Medicine and was selected for the Alpha Omega Alpha medical honors society. He was awarded the W. Barry Wood Student Research Award for his work describing a novel water treatment method for tropical settings using psoralens found naturally in citrus fruit to block DNA transcription and replication in pathogenic organisms. He graduated from Harvard Business School with an MBA and completed his undergraduate education at Yale University, where he founded a non-profit called Water Ecuador, which provided clean and affordable drinking water to thousands of people in a low-income, rural part of Ecuador.



Ed Schlesinger T.E. "Ed" Schlesinger is the Benjamin T. Rome Dean at Johns Hopkins University’s Whiting School of Engineering where he also is a professor in the Department of Electrical and Computer Engineering.










JHAA Event Cancellation and Refund Policy

 Event Date
Wednesday, March 18, 2020
Start Time: 6:00pm
End Time: 8:00pm


800 Boylston Street
Boston, MA 02199

Alumni Relations
1-800-JHU-JHU1 (548-5481)

Status message

Online registration for this event is now closed. For more information or to be placed on a waiting list, please contact